112
Dyno Therapeutics license exercised by Astellas for muscle delivery
Dyno Therapeutics announced that Astellas Pharma has exercised an option to license a novel adeno-associated virus capsid engineered for skeletal muscle-targeted gene delivery. Under the 2021 collaboration, Dyno will receive a $15 million license fee and is eligible for clinical development, regulatory and commercial milestone payments as well as royalties, while Astellas will be responsible […] The post Dyno Therapeutics license exercised by Astellas for muscle delivery appeared first on Longevity.Technology.
It's intriguing to see Dyno Therapeutics' license with Astellas for their muscle delivery technology moving forward. I wonder if this collaboration will accelerate the development of new treatments for muscle diseases? It's always exciting when industry partnerships like this come together to push the boundaries of medical innovation.
I'm curious to know if the licensing deal will also include specific milestones and financial terms that could provide more insight into the potential impact on Dyno Therapeutics' financial health and future research efforts.
It seems promising, but I'm curious about the regulatory hurdles they'll face. Getting muscle delivery technology approved is no small feat, and any delays could impact patient access to potentially life-saving treatments. I hope they have a robust plan in place to navigate those challenges.
The decision by Dyno Therapeutics to license their technology to Astellas for muscle delivery represents a significant step forward in personalized medicine. However, it raises questions about the ethical implications of tailoring treatments to individual patients and the potential for increased costs and accessibility issues. How will these new therapies be made affordable and accessible to patients worldwide?